## Nanoscale



View Article Online

## CORRECTION

Check for updates

Cite this: Nanoscale, 2023, 15, 5092

## Correction: Chiral Se@CeO<sub>2</sub> superparticles for ameliorating Parkinson's disease

Ximing Liu,<sup>a,b</sup> Hongyu Zhang,<sup>a,b</sup> Changlong Hao,\*<sup>a,b</sup> Hua Kuang,<sup>a,b</sup> Chuanlai Xu<sup>a,b</sup> and Liguang Xu\*<sup>a,b</sup>

DOI: 10.1039/d3nr90035e

rsc.li/nanoscale

Correction for 'Chiral Se@CeO<sub>2</sub> superparticles for ameliorating Parkinson's disease' by Ximing Liu *et al.*, *Nanoscale*, 2023, https://doi.org/10.1039/d2nr04534f.

The authors regret an error in Fig. 4C and in Liguang Xu's email address in the original article, and in Fig. S25 and S31 of the ESI. Fig. 4C in the original article showed an incorrect confocal image of D-SP under block clathrin. The corrected Fig. 4C is shown below.

The correct email address for Liguang Xu is as shown herein.

Fig. S25 showed incorrect two-photon luminescence images of MN9D cells incubated with D-SP for 4 h and 10 h, and Fig. S31 showed an incorrect image of the H&E-stained heart with saline treatment.

<sup>a</sup>International Joint Research Laboratory for Biointerface and Biodetection, Jiangnan University, Wuxi, Jiangsu, 214122, People's Republic of China. E-mail: hcl@jiangnan.edu.cn, xlg@jiangnan.edu.cn

<sup>b</sup>State Key Laboratory of Food Science and Technology, Jiangnan University, Jiangsu, People's Republic of China

Open Access Article. Published on 23 February 2023. Downloaded on 7/19/2025 2:48:10 AM.



**Fig. 4** The TPL intensity of NPs from the corresponding TPL images (Fig. S24 to S26). Data are presented as mean  $\pm$  s. d. (n = 5). (B) Two-photon luminescence (TPL) intensity of the SP with different treatments. Data are presented as mean  $\pm$  s. d. (n = 5). (C) Confocal images of MN9D cells after incubating under 4 °C or block caveolin, or block clathrin, or block dynamin. White, SP NPs; blue, DAPI for nuclei. Scale bars, 50  $\mu$ m.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.